Business
Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022
AUSTIN, Texas, Aug. 29, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation
About this update from Spyre Therapeutics, Inc.
[{"type":"text","content":"AUSTIN, Texas, Aug. 29, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced oral and poster presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022 being held in Freiburg, Germany August 30 – September 2. The presentations include perspectives on dietary management of Homocystinuria, which will be given as both an oral and poster presentation, as well as additional safety and efficacy data from the PEACE Phase 3 study of pegzilarginase for the treatment of patients with Arginase 1 Deficiency.\nHomocystinuria Presentations:Title: Dietary management of homocystinuria (HCU) caused by cystathionine beta-synthase (CBS) deficiency: Perspectives from a global cohort of metabolic dietitiansAbstract: SSIEM22-2306Oral Presentation Time: August 31, 11:15 – 11:30 am CESTOral Presentation Session: SM23, SSIEM-DG MeetingPoster Presentation Time: August 31, 6:45 – 8:15 pm CESTPresenter: Danielle Starin, MS, RD, Children's National Hospital, Washington, DC\nPegzilarginase Presentations:Oral Presentation\nTitle: Pegzilarginase efficacy in Arginase 1 Deficiency: Results of the PEACE pivotal phase 3 trialAbstract: SSIEM22-2674Presentation Time: September 1, 3:15 – 3:30 pm CESTSession: PAS4A, Gene and Innovative TherapiesPresenter: Rossana Sanchez Russo, MD, Emory University School of Medicine, Atlanta, Georgia\nPoster Presentation\nTitle: Safety and tolerability of pegzilarginase for Arginase 1 Deficiency in the PEACE pivotal phase 3 clinical trialAbstract: SSIEM22-2687Presentation Time: August 31, 6:45 – 8:15 pm CESTPresenter: Rossana Sanchez Russo, MD, Emory University School of Medicine, Atlanta, Georgia\nAbout Aeglea BioTherapeuticsAeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. Aeglea is investigating AGLE-177 in an ongoing Phase 1/2 clinical trial for the treatment of Homocystinuria. AGLE-177 has been granted Rare Pediatric Disease Designation. Aeglea's other clinical program, pegzilarginase, achieved the primary endpoint of arginine reduction in the PEACE Phase 3 clinical tri...